Audit: QRS - Gamma Oryzanol for Health & Longevity
Audit conducted on 15/08/2026 19:06 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every span traces to ER text: protocol cells to ER Therapeutic Protocol, time cells to the ER Practical Considerations time-to-effect bullet, benefit/risk items to the ER tier headings, gates to Key Interactions & Contraindications, markers to the ER monitoring table. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | The ER’s hedges are carried over — “Absorption is the unresolved problem” mirrors “The unresolved problem is absorption”; “the expected contribution is small” is verbatim ER conclusion wording. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain contraindications (thyroid disease, sitosterolemia, pregnancy/lactation above dietary amounts); no benefit is upgraded and no avoidance instruction is downgraded to a caution. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER “Populations who should avoid Gamma Oryzanol” list; Key Interactions only from the ER interaction bullets; nothing from Benefit-Modifying Factors or Risk-Modifying Factors is re-categorised. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, no NCT identifiers, no author names, and no brand names anywhere. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No source, author, organisation, or institution is named in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Flat, declarative, evidence-first register throughout, matching the ER’s own restraint about a compound whose active fraction is disputed. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Numeric anchors (300 mg, 30 mL, 8,000–11,000 ppm, 4/12 weeks, marker targets) sit alongside plain-language framing that leaves the decision with the reader. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Statements describe what trials used and what the ER found; no imperative instruction is issued. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Monitoring targets and cadence are presented as the ER’s stated ranges and trial timescales, not as orders. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, “should”, or “you should” in the QRS body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the sheet. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Marker names are spelled out (“High-sensitivity C-reactive protein”, “Glycated hemoglobin”, “Alanine aminotransferase”); “plaque-forming cholesterol” is used in At-A-Glance in place of LDL. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate items are noun phrases, benefit/risk tiers are semicolon-separated fragments, monitoring “why” cells are single clauses. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address in any span. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | The sheet assumes access to apolipoprotein B, hs-CRP, and a plant sterol panel, and frames the compound as an addition to an existing programme. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | The 30 mL oil delivery vehicle, split dosing with meals, and an eleven-marker monitoring panel all assume a high-effort reader. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Specialist assays (plasma sitosterol and campesterol) and tighter-than-conventional functional targets place it well outside general-population material. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance states plainly that within a programme already addressing blood fats the expected contribution is small — the audience-specific verdict rather than the general one. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur; the page title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Terminology follows the ER exactly (“Under-active thyroid”, “hot flushes”, “renal impairment”, “loss-of-function”); no consumer-grade substitutions appear. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings match the template byte-for-byte (lines 445, 491, 538, 569, 584, 609, 637, 641–643, 821). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variables are present, with marker_#_* expanded to markers 1–11 and qualitative_item_# expanded to items 1–5 — 72 spans in total. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A structural diff against the template shows only content substitution inside variable spans; the website="evidence_review", website="audit", and website="full_review" spans, the CSS block, and the footer disclaimer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section feeding a QRS field is empty — Protocol, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, and Monitoring are all populated. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol cell labels are the ER’s bold labels verbatim: “Standard lipid dose”, “Rice bran oil as the delivery vehicle”, “Best time of day”; monitoring row labels are the ER biomarker table’s own names. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels (“Lipid changes”, “Inflammation marker and glycated hemoglobin”, “Skin hydration”) are lifted word-for-word from the ER’s single time-to-effect bullet, which carries no per-item bold label of its own. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in the file; the ER’s “⚠️ Conflicted” markers on three headings are stripped, and tiering is carried by the bold “High/Medium/Low/Speculative” labels plus the green/red card CSS. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to its minimum: gate items are noun phrases with parentheticals trimmed to drug names and thresholds, benefit/risk tiers collapse to one line each, and monitoring “why” cells are cut to a single clause. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: one comment opening immediately after <!doctype html> on line 1, closing before the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the descriptive text “QRS — Metadata (invisible, parsed by audit tooling)” precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment above <html>; no element in the body repeats any metadata value. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:04" is quoted, correctly so because the value contains a colon; every other value is bare and untrimmed of nothing. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: gamma_oryzanol_2026-0825-1617_Opus_ER.md, matching the ER’s own filename frontmatter field. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the head of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0815-1850, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version, no qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version number, with no context-window or tier qualifier appended. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: gamma_oryzanol_2026-0825-1617_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine fields including the tooling-added git_user and git_issue; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Gamma Oryzanol for Health & Longevity - Quick Reference Sheet”, with the ampersand correctly entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Gamma Oryzanol for Health & Longevity”, matching the ER’s canonical_topic. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/15/2026”, the correct reformatting of qrs_creation_date: 2026-0815-1850. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, identical to the frontmatter qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header carries only the title and the template subline; the ER’s “Also known as” list and prompt version are not reproduced. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Four sentences compress the Conclusion’s four paragraphs: Japanese licensing history, the lipid signal via rice bran oil, the safety picture, and the absorption problem with the marginal expected contribution. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 52 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “six decades” from the Conclusion’s opening; the cholesterol sentence from its second paragraph; “Side effects appear rare and mild” verbatim from the fourth; “the expected contribution is small” verbatim from the closing sentence. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “plaque-forming cholesterol” replaces LDL; no acronyms, and no clinical-register words such as “adjunct” or “modality”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial, author, year, or sample size is named. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | The lipid effect is characterised qualitatively as “modest lowering” with no mg/dL or percentage figure. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items map one-to-one onto the ER’s “Populations who should avoid Gamma Oryzanol” list. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoidance populations are present and none is invented: sitosterolemia/ABCG5-ABCG8, rice allergy, thyroid disease, pregnancy and lactation, renal impairment. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 572–579: five discrete <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER trailing clause is stripped: “— deliberate plant sterol loading is contraindicated”, “, since the compound lowers thyroid-stimulating hormone”, “, where safety data are absent”, and “— purified oryzanol is not implicated” are all absent. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | The renal threshold survives as “(filtration rate below 30 mL/min/1.73 m²)”, trimmed from the ER’s longer gloss but with the numeric cut-off intact; “at doses above ordinary dietary amounts” is likewise retained on the pregnancy item. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication bullets use no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names five such populations, and the section is correctly populated rather than left empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items trace to the ER’s interaction bullets in that section. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Eight of the ER’s nine interaction bullets are carried; the only omission is “Liver drug-metabolizing enzymes”, which the ER itself grades “no action required beyond routine review” and so does not change how the intervention is used. No contraindication is duplicated here. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 587–599: eight discrete <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s severity grades, mechanisms, and mitigations (“Additive LDL lowering through a separate mechanism”, “Separation of dosing by at least four hours”, “Severity: caution”) are all stripped; each item is a bare noun phrase. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named agents are preserved throughout — statins, ezetimibe, cholestyramine and colesevelam, fortified spreads and sterol tablets, the six additive-lipid supplements, and the vitamin E / omega-3 / niacin combination; the ER’s in-paren definition of statins is trimmed to the drug names alone. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets use no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names multiple additive and competing exposures, and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells draw on the ER Therapeutic Protocol bullets; the split-dosing detail in cell three comes from that section’s “Single versus split dosing” bullet. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, delivery vehicle, and timing — the three decisions a reader must make before starting; the remaining ER bullets (half-life, genetics, sex, age) are descriptive rather than actionable. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies twelve protocol bullets, so all three action sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry substantive ER-derived content; values are concrete (“300 mg daily”, “30 mL oil daily”, “With the largest fat-containing meal”) and each sub adds the dose range, the oryzanol concentration, or the split-dosing pattern. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | The ER’s time-to-effect bullet names exactly three windows — lipids, inflammation marker plus glycated hemoglobin, and skin hydration — and all three are carried. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Lipids (the ER’s sole High benefit) first, inflammation and glycemic markers (Medium) second, skin hydration (Low) third. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated with the ER’s own figures: “4 weeks”, “12 weeks”, “4–8 weeks”, each with the ER sentence as the sub. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides a dedicated time-to-effect bullet, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten benefit statements correspond to the ten ER benefit headings across the four tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (lines 540, 545, 551, 558). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading reduced to a noun phrase; none of the ER’s “Magnitude:” figures (6.9–15.1 mg/dL, 0.7 percentage points, 5.73 points) appears. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses occur in any benefit item; the ER’s inline glosses such as “(low-density lipoprotein, the cholesterol fraction that drives arterial plaque)” are absent. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven risk statements correspond to the seven ER risk headings across the four tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (lines 611, 614, 620, 626). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading as a noun phrase; the Yusho case detail, the “under 5%” absorption figure, and the “over 1,800 people” magnitude are all omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses occur in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Marker names, targets, and rationales all come from the ER’s biomarker table in Monitoring Protocol & Defining Success. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eleven ER table rows are present in the same order: LDL cholesterol, apolipoprotein B, total cholesterol, triglycerides, HDL cholesterol, hs-CRP, glycated hemoglobin, fasting glucose, thyroid-stimulating hormone, alanine aminotransferase, and plasma sitosterol and campesterol. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 812: reproduces the ER’s cadence paragraph — lipid panel at 4 and 12 weeks then every 6–12 months, inflammation marker and glycated hemoglobin at 12 weeks, thyroid-stimulating hormone at 12 weeks where thyroid disease is known. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five items come from the ER’s “Qualitative markers worth tracking alongside the laboratory values” list. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers are present, with the ER’s trailing rationale clauses trimmed: digestive comfort and stool consistency, hot flushes, skin dryness, energy and daytime alertness, and new itching, rash or swelling. |
Issues 15/08/2026 19:06
Pass rate 100.00%. No issues found.
Issues 15/08/2026 19:00
- 4.3 — Interaction labels altered: In Key Interactions (lines 590, 591, 596) the ER labels “Over-the-counter plant sterol and stanol products” and “Over-the-counter fat-soluble vitamin and carotenoid products” are abbreviated to drop “Over-the-counter”, and “Supplement combinations tested together” is paraphrased as “Combined formulations tested together”.
Fixes 15/08/2026 19:00
- 4.3 — Interaction labels restored: Restored the ER’s verbatim labels in Key Interactions — “Over-the-counter” was re-added to the plant sterol/stanol and fat-soluble vitamin/carotenoid items, and “Combined formulations tested together” was changed back to “Supplement combinations tested together”.
Issues 15/08/2026 18:55
- 9.4 — Trailing explanation in interaction item: The final Key Interactions item at line 597, “Brown rice-based diet, which already supplies dietary oryzanol”, carries an explanatory relative clause that item 9.4 requires stripped.
Fixes 15/08/2026 18:55
- 9.4 — Trailing explanation stripped: Shortened the final Key Interactions item from “Brown rice-based diet, which already supplies dietary oryzanol” to “Brown rice-based diet”.